SHI Meipan, SHI Caiping, DU Chixin. Advances in the Diagnosis and Treatment for Ocular Complication on Mucopolysaccharidosis[J]. Journal of Rare Diseases, 2023, 2(3): 450-454. DOI: 10.12376/j.issn.2097-0501.2023.03.018
Citation: SHI Meipan, SHI Caiping, DU Chixin. Advances in the Diagnosis and Treatment for Ocular Complication on Mucopolysaccharidosis[J]. Journal of Rare Diseases, 2023, 2(3): 450-454. DOI: 10.12376/j.issn.2097-0501.2023.03.018
shu

Advances in the Diagnosis and Treatment for Ocular Complication on Mucopolysaccharidosis

  • 1.

    Department of Ophthalmology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

  • 2.

    Department of Ophthalmology, Children′s Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

More Information
  • Received Date: August 07, 2022
  • Accepted Date: September 25, 2022
  • Available Online: September 08, 2023
2097-0501/©2023 Editorial Office of Journal of Rare Diseases This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/)
    Graphical Abstract
    • Abstract

  • Mucopolysaccharidosis is a series of rare diseases where a lack of an enzyme affecting mucopolysaccharides metabolism in the patients′ lysosome induces the intracellular deposition of the mucopolysaccharides, and causes ocular and organ-related complications. Ocular complications included corneal opacity, glaucoma, ametropia, strabismus, and chorioretinopathy. This review summarizes the mechanisms, clinical manifestations, specific ophthalmological examinations, and treatments for offering the ophthalmological knowledge to diagnose and begin treatment earlier.

    • FullText(HTML)
    • References (26)
  • [1]
    Lin HY, Chuang CK, Huang YH, et al. Causes of death and clinical characteristics of 34 patients with mucopolysaccharidosis Ⅱ in Taiwan from 1995-2012[J]. Orphanet J Rare Dis, 2016, 11(1): 85. doi: 10.1186/s13023-016-0471-6
    [2]
    Mandolfo O, Parker H, Bigger B. Innate immunity in mucopolysaccharide diseases[J]. Int J Mol Sci, 2022, 23(4): 1999. doi: 10.3390/ijms23041999
    [3]
    Tomatsu S, Pitz S, Hampel U. Ophthalmological findings in mucopolysaccharidoses[J]. J Clin Med, 2019, 8(9): 1467. doi: 10.3390/jcm8091467
    [4]
    Khan SA, Peracha H, Ballhausen D, et al. Epidemiology of mucopolysaccharidoses[J]. Mol Genet Metab, 2017, 121(3): 227-240. doi: 10.1016/j.ymgme.2017.05.016
    [5]
    Chen X, Qiu W, Ye J, et al. Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China[J]. J Hum Genet, 2016, 61(4): 345-349. doi: 10.1038/jhg.2015.155
    [6]
    Wood T, Bodamer OA, Burin MG, et al. Expert recommendations for the laboratory diagnosis of MPS VI[J]. Mol Genet Metab, 2012, 106(1): 73-82. doi: 10.1016/j.ymgme.2012.02.005
    [7]
    Wood TC, Harvey K, Beck M, et al. Diagnosing mucopolysaccharidosis IVA[J]. J Inherit Metab Dis, 2013, 36(2): 293-307. doi: 10.1007/s10545-013-9587-1
    [8]
    Ganesh A, Bruwer Z, Al-Thihli K. An update on ocular involvement in mucopolysaccharidoses[J]. Curr Opin Ophthalmol, 2013, 24(5): 379-388. doi: 10.1097/ICU.0b013e3283644ea1
    [9]
    Fahnehjelm KT, Ashworth JL, Pitz S, et al. Clinical guidelines for diagnosing and managing ocular manifestations in children with mucopolysaccharidosis[J]. Acta Ophthalmol, 2012, 90(7): 595-602. doi: 10.1111/j.1755-3768.2011.02280.x
    [10]
    Nowaczyk MJ, Clarke JT, Morin JD. Glaucoma as an early complication of Hurler's disease[J]. Arch Dis Child, 1988, 63(9): 1091-1093. doi: 10.1136/adc.63.9.1091
    [11]
    Ashworth J, Flaherty M, Pitz S, et al. Assessment and diagnosis of suspected glaucoma in patients with mucopolysaccharidosis[J]. Acta Ophthalmol, 2015, 93(2): e111-e117. doi: 10.1111/aos.12607
    [12]
    Traboulsi EI, Maumenee IH. Ophthalmologic findings in mucolipidosis iii (pseudo-Hurler polydystrophy)[J]. Am J Ophthalmol, 1986, 102(5): 592-597. doi: 10.1016/0002-9394(86)90529-5
    [13]
    Fahnehjelm KT, Törnquist AL, Malm G, et al. Ocular findings in four children with mucopolysaccharidosis Ⅰ-Hurler (MPS Ⅰ-H) treated early with haematopoietic stem cell transplantation[J]. Acta Ophthalmol Scand, 2006, 84(6): 781-785. doi: 10.1111/j.1600-0420.2006.00743.x
    [14]
    Schumacher RG, Brzezinska R, Schulze-Frenking G, et al. Sonographic ocular findings in patients with mucopolysaccharidoses Ⅰ, Ⅱ and Ⅵ[J]. Pediatr Radiol, 2008, 38(5): 543-550. doi: 10.1007/s00247-008-0788-y
    [15]
    Summers CG, Ashworth JL. Ocular manifestations as key features for diagnosing mucopolysaccharidoses[J]. Rheumatology(Oxford), 2011, 50 Suppl 5: v34-v40. doi: 10.1093/rheumatology/ker392
    [16]
    Tse DY, Lotfi P, Simons DL, et al. Electrophysiological and histological characterization of rod-cone retinal degeneration and microglia activation in a mouse model of mucopolysaccharidosis type iiib[J]. Sci Rep, 2015, 5: 17143. doi: 10.1038/srep17143
    [17]
    Mocan MC, Eldem B, Irkec M. In vivo confocal micros-copic findings of two siblings with Maroteaux-Lamy syndrome[J]. Cornea, 2007, 26(1): 90-93. doi: 10.1097/ICO.0b013e31802be383
    [18]
    Wasielica-Poslednik J, Butsch C, Lampe C, et al. Comparison of rebound tonometry, perkins applanation tonometry and ocular response analyser in mucopolysaccharidosis patients[J]. PLoS One, 2015, 10(8): e0133586. doi: 10.1371/journal.pone.0133586
    [19]
    Zhang JR, Wang JH, Lin HZ, et al. Anterior chamber angles in different types of mucopolysaccharidoses[J]. Am J Ophthalmol, 2020, 212: 175-184. doi: 10.1016/j.ajo.2020.01.007
    [20]
    Huang CT, Chu SY, Lee YC. Optical coherence tomography of chorioretinopathy caused by mucopolysaccharidoses[J]. Ophthalmology, 2015, 122(7): 1535-1537. doi: 10.1016/j.ophtha.2015.01.015
    [21]
    Kowalski T, Ruddle JB, de Jong G, et al. Expanding the phenotype of mucopolysaccharidosis type Ⅱ retinopathy[J]. Ophthalmic Genet, 2021, 42(5): 631-636. doi: 10.1080/13816810.2021.1938141
    [22]
    Ohden KL, Pitz S, Ashworth J, et al. Outcomes of keratoplasty in the mucopolysaccharidoses: an international perspective[J]. Br J Ophthalmol, 2017, 101(7): 909-912 doi: 10.1136/bjophthalmol-2016-308807
    [23]
    Veerappan M, Chak G, Shieh C, et al. Atypical presentation of acute angle-closure glaucoma in maroteaux-lamy mucopolysaccharidosis with patent prophylactic laser peripheral iridotomy: a case report[J]. Perm J, 2017, 21: 17-012.
    [24]
    Fahnehjelm KT, Törnquist AL, Winiarski J. Ocular axial length and corneal refraction in children with mucopolysaccharidosis (MPS Ⅰ-Hurler)[J]. Acta Ophthalmol, 2012, 90(3): 287-290. doi: 10.1111/j.1755-3768.2010.01934.x
    [25]
    Hennig AK, Ogilvie JM, Ohlemiller KK, et al. AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS Ⅶ mice[J]. Mol Ther, 2004, 10(1): 106-116. doi: 10.1016/j.ymthe.2004.03.018
    [26]
    Wraith JE. Lysosomal disorders[J]. Semin Neonatol, 2002, 7(1): 75-83. doi: 10.1053/siny.2001.0088
    • Related Articles

  • Related Articles

    [1]XU Yiming, PENG Huiming, LYU Shuaijie, TONG Peijian, LI Hu, CHEN Fenyong, WANG Haibin, YANG Qi, CHEN Bin, YUAN Zhen, BI Rongxiu, FENG Jianmin, JIANG Wenxue, ZHOU Zongke, FAN Meng, LI Xiang, LEI Guanghua, WENG Xisheng. A Survey of the Current Status of Surgical Treatment of Hemophilic Osteoarthropathy in China Mainland 17 Grade A General Hospitals[J]. Journal of Rare Diseases, 2023, 2(4): 516-522. DOI: 10.12376/j.issn.2097-0501.2023.04.008
    [2]YE Changxiong, SUN Jing. Development and Utilization of "One-Stop Finance Service" forRelief Fund for Hemophilia Patients[J]. Journal of Rare Diseases, 2022, 1(4): 474-478. DOI: 10.12376/j.issn.2097-0501.2022.04.019
    [3]LI Shunping, DOU Lei, FANG Yunhai. Current Situation and Prospect of Pharmacoeconomic Evaluation of Hemophilia in China[J]. Journal of Rare Diseases, 2022, 1(4): 468-473. DOI: 10.12376/j.issn.2097-0501.2022.04.018
    [4]ZHANG Jing, JU Mankai, ZHANG Kemin, CHEN Lingling, WANG Yuhua, ZHANG Lei, YANG Renchi, XUE Feng. A Case of Hemophilia B with Abdominal and Pelvic Pseudotumor[J]. Journal of Rare Diseases, 2022, 1(4): 456-460. DOI: 10.12376/j.issn.2097-0501.2022.04.016
    [5]GUO Xinjuan, DING Xiaoling, LI Dongshuang, LI Jun. Practical Guidance for Ultrasonic Evaluation of Hemophilic Arthropathy[J]. Journal of Rare Diseases, 2022, 1(4): 449-455. DOI: 10.12376/j.issn.2097-0501.2022.04.015
    [6]Hemophilia Treatment Center Collaborative Network of China. Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A[J]. Journal of Rare Diseases, 2022, 1(4): 428-434. DOI: 10.12376/j.issn.2097-0501.2022.04.011
    [7]DAI Xinyue, ZHANG Lei. Status and Prospect of Gene Therapy for Hemophilia[J]. Journal of Rare Diseases, 2022, 1(4): 386-390. DOI: 10.12376/j.issn.2097-0501.2022.04.005
    [8]CHENG Yan, FANG Yunhai, ZHANG Xinsheng. Current Status and Discussion of Hemophilia Aid System[J]. Journal of Rare Diseases, 2022, 1(4): 375-379. DOI: 10.12376/j.issn.2097-0501.2022.04.003
    [9]XUE Feng, YANG Renchi. Establishment and Evolution of China National Hemophilia Registry[J]. Journal of Rare Diseases, 2022, 1(4): 370-374. DOI: 10.12376/j.issn.2097-0501.2022.04.002
    [10]YANG Renchi. Establishment of Care System for Hemophilia in China: Current Status and Future Prospect[J]. Journal of Rare Diseases, 2022, 1(4): 365-369. DOI: 10.12376/j.issn.2097-0501.2022.04.001

Catalog

    Get Citation
    PDF
    XML
    Article views (99) PDF downloads (18) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles
    Links Chinese Medical Association

    Official account

    WeChat

    RSS Email alert

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return